Innovative Cellular Therapeutics Holdings Ltd - 17 Jul 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: 10%+ Owner
Issuer ticker: LYEL
Reported as of: 17 Jul 2026
Net transaction value: -$137
SEC form: 4
Accepted by SEC: 20 Jul 2026, 14:55:54 UTC
Prior SEC filing: 17 Jul 2026
Source filing: View source filing
Reporting owner signature: Innovative Cellular Therapeutics Holdings Limited By: /s/ Lei Xiao Name: Lei Xiao Title: Chief Executive Officer

Key filing fact

Innovative Cellular Therapeutics Holdings Ltd filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 20 Jul 2026.

Key facts

This page summarizes Innovative Cellular Therapeutics Holdings Ltd's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 20 Jul 2026, 14:55.

Change

Previous filing in this sequence was filed on 17 Jul 2026.
Current net transaction value: -$137.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002095697 Primary reporting owner

Innovative Cellular Therapeutics Holdings Ltd

Relationship: 10%+ Owner
Address: 190 ELGIN AVENUE, GEORGE TOWN, CAYMAN ISLANDS
Signature: Innovative Cellular Therapeutics Holdings Limited By: /s/ Lei Xiao Name: Lei Xiao Title: Chief Executive Officer
Signature date: 18 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LYEL transaction

Common Stock

Sale

Transaction value: $137
Shares: -10
Change %: -0%
Price: $13.70
Shares after: 2,857,480
Date: 17 Jul 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Reflects 2,857,490 shares of Common Stock beneficially owned by the Reporting Person immediately prior to the reported transaction, less the 10 shares sold.